Background & Aims The development of direct-acting antiviral agents (DAAs) is a major step
forward in the treatment of hepatitis C (HCV). The aims of the study were to evaluate the
efficacy and tolerability of DAAs in kidney transplant (KT) recipients. Methods Hepa-C is a
Spanish registry of patients treated with DAAs in which clinical, virological and analytical
data were prospectively included. We report on the data from 103 KT recipients who
received DAAs. Results The most commonly used DAAs combinations were …

… The development of direct acting antiviral agents (DAA) with better efficacy and safety
profiles has completely changed the scenario. The aims of this study were: 1) to evaluate
efficacy and tolerability of DAA combinations in KT recipients and 2) to determine the impact
of therapy on renal function and immunosuppression (IS) trough levels. … Conclusions:
Antiviral therapy with DAA was efficacious and well tolerated in KT recipients treated in
clinical practice. Allograft dysfunction was rarely observed, but a significant proportion of …